- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03914612
Test af tilføjelsen af immunterapilægemidlet Pembrolizumab til den sædvanlige kemoterapibehandling (Paclitaxel og Carboplatin) i trin III-IV eller tilbagevendende endometriecancer
En fase III randomiseret, placebokontrolleret undersøgelse af Pembrolizumab (MK-3475, NSC #776864) i tillæg til paclitaxel og carboplatin til målbar trin III eller IVA, trin IVB eller tilbagevendende endometriecancer
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
Studieoversigt
Status
Betingelser
- Endometrie clear cell adenocarcinoma
- Endometrielt dedifferentieret karcinom
- Endometrie Endometrioid Adenocarcinom
- Endometrie blandet cellet adenokarcinom
- Endometrial serøst adenokarcinom
- Endometrielt udifferentieret karcinom
- Tilbagevendende endometrisk adenokarcinom
- Tilbagevendende endometriekarcinom
- Tilbagevendende endometrie clear cell adenocarcinoma
- Tilbagevendende endometrielt dedifferentieret karcinom
- Tilbagevendende endometrieendometrioid adenokarcinom
- Tilbagevendende endometrie blandet cellet adenokarcinom
- Tilbagevendende endometrie serøs adenokarcinom
- Tilbagevendende endometrielt udifferentieret karcinom
- Trin III livmoderkorpuscarcinom eller carcinosarkom AJCC V8
- Trin IV -livmoderkorpuscarcinom eller carcinosarkom AJCC V8
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer.
SECONDARY OBJECTIVES:
I. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) for each treatment arm.
II. To evaluate blinded independent central review (BICR) assessed or investigator assessed objective response rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by treatment arm and by mismatch repair (MMR) immunohistochemistry (IHC) status in patients who enter the study with measurable disease.
III. To evaluate BICR assessed or investigator assessed duration of response (DOR) by treatment arm and by MMR IHC status in patients who enter the study with measurable disease.
IV. To evaluate the effect of pembrolizumab (MK-3475) on overall survival (OS) in patients with mismatch repair protein proficient (pMMR) or mismatch repair deficiency (dMMR).
V. To determine whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with improved patient reported physical function as measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-physical function scale (short form), quality of life as measured with the Functional Assessment of Cancer Therapy (FACT) - Endometrial Trial Outcome Index (En TOI) and worsened fatigue as measured with the PROMIS-Fatigue scale (short form) in the pMMR patients.
VI. To determine concordance between institutional MMR IHC testing and centralized MMR IHC.
EXPLORATORY OBJECTIVES:
I. To explore the correlation between patient-reported physical function as measured with the PROMIS-physical function scale (short form) and quality of life as measure with the FACT-En TOI.
II. To explore whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with self-reported neurotoxicity as measured with the FACT/Gynecologic Oncology Group Neurotoxicity (GOG-Ntx) subscale (short) and the extent to which patients differ on their self-reported bother from side effects of cancer therapy in the pMMR patients.
III. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer by Programmed Death Ligand 1 (PD-L1) IHC (positive versus [vs] negative).
IV. To assess the association between PD-L1 IHC (positive vs negative) and mismatch repair status (pMMR and dMMR).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I:
COMBINATION PHASE: Patients receive placebo intravenously (IV) over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease may continue treatment for up to a total 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm I will not receive additional placebo infusions.
ARM II:
COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo computed tomography (CT) scan throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1C 6Z8
- The Moncton Hospital
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Royal Victoria Regional Health Centre
-
Greater Sudbury, Ontario, Canada, P3E 5J1
- Health Sciences North
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Program
-
Oshawa, Ontario, Canada, L1G 2B9
- Lakeridge Health Oshawa
-
Sault Ste. Marie, Ontario, Canada, P6B 0A8
- Algoma District Cancer Program Sault Area Hospital
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Canada, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Laval, Quebec, Canada, H7M 3L9
- Hopital de la Cite-de-la-Sante
-
Montreal, Quebec, Canada, H2X 3E4
- CHUM - Centre Hospitalier de l'Universite de Montreal
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage, Alaska, Forenede Stater, 99508
- Alaska Women's Cancer Care
-
-
Arizona
-
Goodyear, Arizona, Forenede Stater, 85338
- CTCA at Western Regional Medical Center
-
-
Arkansas
-
Jonesboro, Arkansas, Forenede Stater, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
Little Rock, Arkansas, Forenede Stater, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Baldwin Park, California, Forenede Stater, 91706
- Kaiser Permanente-Baldwin Park
-
Bellflower, California, Forenede Stater, 90706
- Kaiser Permanente-Bellflower
-
Berkeley, California, Forenede Stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Clovis, California, Forenede Stater, 93611
- Community Cancer Institute
-
Duarte, California, Forenede Stater, 91010
- City of Hope Comprehensive Cancer Center
-
Harbor City, California, Forenede Stater, 90710
- Kaiser Permanente South Bay
-
Irvine, California, Forenede Stater, 92618
- Kaiser Permanente-Irvine
-
La Jolla, California, Forenede Stater, 92093
- UC San Diego Moores Cancer Center
-
Lancaster, California, Forenede Stater, 93534
- City of Hope Antelope Valley
-
Los Angeles, California, Forenede Stater, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Forenede Stater, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forenede Stater, 90095
- UCLA / Jonsson Comprehensive Cancer Center
-
Los Angeles, California, Forenede Stater, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Forenede Stater, 90033
- Los Angeles General Medical Center
-
Mountain View, California, Forenede Stater, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Oakland, California, Forenede Stater, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Forenede Stater, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Forenede Stater, 92868
- Saint Joseph Hospital - Orange
-
Rancho Mirage, California, Forenede Stater, 92270
- Eisenhower Medical Center
-
Redding, California, Forenede Stater, 96001
- Mercy Regional Cancer Center
-
Redding, California, Forenede Stater, 96002
- Mercy Oncology Center
-
Riverside, California, Forenede Stater, 92505
- Kaiser Permanente-Riverside
-
Roseville, California, Forenede Stater, 95661
- Kaiser Permanente-Roseville
-
Sacramento, California, Forenede Stater, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Forenede Stater, 95814
- Kaiser Permanente Downtown Commons
-
Sacramento, California, Forenede Stater, 95816
- Mercy Cancer Center - Sacramento
-
San Diego, California, Forenede Stater, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, Forenede Stater, 92134
- Naval Medical Center -San Diego
-
San Francisco, California, Forenede Stater, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Forenede Stater, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Forenede Stater, 94115
- California Pacific Medical Center-Pacific Campus
-
San Francisco, California, Forenede Stater, 94110
- Zuckerberg San Francisco General Hospital
-
San Jose, California, Forenede Stater, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, Forenede Stater, 94577
- Kaiser Permanente San Leandro
-
San Marcos, California, Forenede Stater, 92078
- Kaiser Permanente-San Marcos
-
Santa Clara, California, Forenede Stater, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
South Pasadena, California, Forenede Stater, 91030
- City of Hope South Pasadena
-
South San Francisco, California, Forenede Stater, 94080
- Kaiser Permanente-South San Francisco
-
Sunnyvale, California, Forenede Stater, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Upland, California, Forenede Stater, 91786
- City of Hope Upland
-
Vallejo, California, Forenede Stater, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Forenede Stater, 94596
- Kaiser Permanente-Walnut Creek
-
Walnut Creek, California, Forenede Stater, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forenede Stater, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Forenede Stater, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Forenede Stater, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Forenede Stater, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Forenede Stater, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Forenede Stater, 80631
- Banner North Colorado Medical Center
-
Loveland, Colorado, Forenede Stater, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Forenede Stater, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
-
Connecticut
-
Danbury, Connecticut, Forenede Stater, 06810
- Danbury Hospital
-
Guilford, Connecticut, Forenede Stater, 06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford, Connecticut, Forenede Stater, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford, Connecticut, Forenede Stater, 06102
- Hartford Hospital
-
New Britain, Connecticut, Forenede Stater, 06050
- The Hospital of Central Connecticut
-
New Haven, Connecticut, Forenede Stater, 06520
- Yale University
-
North Haven, Connecticut, Forenede Stater, 06473
- Yale-New Haven Hospital North Haven Medical Center
-
Norwalk, Connecticut, Forenede Stater, 06856
- Norwalk Hospital
-
Stamford, Connecticut, Forenede Stater, 06904
- Stamford Hospital/Bennett Cancer Center
-
Torrington, Connecticut, Forenede Stater, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Forenede Stater, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury, Connecticut, Forenede Stater, 06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford, Connecticut, Forenede Stater, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark, Delaware, Forenede Stater, 19713
- Helen F Graham Cancer Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- MedStar Washington Hospital Center
-
Washington D.C., District of Columbia, Forenede Stater, 20016
- Sibley Memorial Hospital
-
-
Florida
-
Bradenton, Florida, Forenede Stater, 34205
- Florida Cancer Specialists - Bradenton Cancer Center
-
Sarasota, Florida, Forenede Stater, 34239
- Sarasota Memorial Hospital
-
Sarasota, Florida, Forenede Stater, 34232
- Florida Cancer Specialists - Sarasota
-
Sarasota, Florida, Forenede Stater, 34239
- Florida Cancer Specialists - Sarasota Downtown
-
Venice, Florida, Forenede Stater, 34285
- Florida Cancer Specialists - Venice Island
-
Venice, Florida, Forenede Stater, 34275
- Florida Cancer Specialists - Venice Pinebrook
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Forenede Stater, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Forenede Stater, 30342
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Forenede Stater, 30303
- Grady Health System
-
Atlanta, Georgia, Forenede Stater, 30342
- Northside Hospital
-
Austell, Georgia, Forenede Stater, 30106
- WellStar Cobb Hospital
-
Fayetteville, Georgia, Forenede Stater, 30214
- Piedmont Fayette Hospital
-
Gainesville, Georgia, Forenede Stater, 30501
- Northeast Georgia Medical Center-Gainesville
-
Marietta, Georgia, Forenede Stater, 30060
- Wellstar Kennestone Hospital
-
Marietta, Georgia, Forenede Stater, 30060
- WellStar Health System Inc
-
Newnan, Georgia, Forenede Stater, 30265
- CTCA at Southeastern Regional Medical Center
-
Roswell, Georgia, Forenede Stater, 30076
- WellStar North Fulton Hospital
-
Savannah, Georgia, Forenede Stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Forenede Stater, 31404
- Memorial Health University Medical Center
-
Smyrna, Georgia, Forenede Stater, 30080
- WellStar Vinings Health Park
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Forenede Stater, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forenede Stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forenede Stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Forenede Stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forenede Stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Forenede Stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
Chicago, Illinois, Forenede Stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Forenede Stater, 60612
- University of Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, Forenede Stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forenede Stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Forenede Stater, 62401
- Crossroads Cancer Center
-
Evanston, Illinois, Forenede Stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Geneva, Illinois, Forenede Stater, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Forenede Stater, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Harvey, Illinois, Forenede Stater, 60426
- Ingalls Memorial Hospital
-
Highland Park, Illinois, Forenede Stater, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon, Illinois, Forenede Stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Forenede Stater, 60153
- Loyola University Medical Center
-
New Lenox, Illinois, Forenede Stater, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Forenede Stater, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Forenede Stater, 60462
- University of Chicago Medicine-Orland Park
-
Springfield, Illinois, Forenede Stater, 62702
- Springfield Clinic
-
Urbana, Illinois, Forenede Stater, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Forenede Stater, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Zion, Illinois, Forenede Stater, 60099
- Midwestern Regional Medical Center
-
-
Indiana
-
Crown Point, Indiana, Forenede Stater, 46307
- Northwest Cancer Center - Crown Point
-
Dyer, Indiana, Forenede Stater, 46311
- Northwest Oncology LLC
-
Hobart, Indiana, Forenede Stater, 46342
- Northwest Cancer Center - Hobart
-
Hobart, Indiana, Forenede Stater, 46342
- Saint Mary Medical Center
-
Indianapolis, Indiana, Forenede Stater, 46237
- Franciscan Health Indianapolis
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Forenede Stater, 46219
- Community Cancer Center East
-
Indianapolis, Indiana, Forenede Stater, 46227
- Community Cancer Center South
-
Indianapolis, Indiana, Forenede Stater, 46256
- Community Cancer Center North
-
Indianapolis, Indiana, Forenede Stater, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
Indianapolis, Indiana, Forenede Stater, 46312
- Saint Catherine Hospital
-
Mooresville, Indiana, Forenede Stater, 46158
- Franciscan Health Mooresville
-
Munster, Indiana, Forenede Stater, 46321
- The Community Hospital
-
Munster, Indiana, Forenede Stater, 46321
- Women's Diagnostic Center - Munster
-
Valparaiso, Indiana, Forenede Stater, 46383
- Northwest Cancer Center - Valparaiso
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kansas
-
Fairway, Kansas, Forenede Stater, 66205
- University of Kansas Clinical Research Center
-
Kansas City, Kansas, Forenede Stater, 66160
- University of Kansas Cancer Center
-
Overland Park, Kansas, Forenede Stater, 66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood, Kansas, Forenede Stater, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Edgewood, Kentucky, Forenede Stater, 41017
- Saint Elizabeth Healthcare Edgewood
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Forenede Stater, 70808
- Our Lady of The Lake
-
Baton Rouge, Louisiana, Forenede Stater, 70817
- Woman's Hospital
-
Baton Rouge, Louisiana, Forenede Stater, 70817
- Our Lady of the Lake Medical Oncology
-
Baton Rouge, Louisiana, Forenede Stater, 70808
- Our Lady of the Lake Physician Group
-
Metairie, Louisiana, Forenede Stater, 70006
- East Jefferson General Hospital
-
New Orleans, Louisiana, Forenede Stater, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Forenede Stater, 70112
- University Medical Center New Orleans
-
New Orleans, Louisiana, Forenede Stater, 70115
- Ochsner Baptist Medical Center
-
-
Maine
-
Augusta, Maine, Forenede Stater, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, Forenede Stater, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Forenede Stater, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer, Maine, Forenede Stater, 04412
- Lafayette Family Cancer Center-EMMC
-
Rockport, Maine, Forenede Stater, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Forenede Stater, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Forenede Stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Annapolis, Maryland, Forenede Stater, 21401
- Luminis Health Anne Arundel Medical Center
-
Baltimore, Maryland, Forenede Stater, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore, Maryland, Forenede Stater, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Forenede Stater, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Forenede Stater, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Forenede Stater, 21201
- University of Maryland/Greenebaum Cancer Center
-
Baltimore, Maryland, Forenede Stater, 21229
- Saint Agnes Hospital
-
Bel Air, Maryland, Forenede Stater, 21014
- UM Upper Chesapeake Medical Center
-
Bethesda, Maryland, Forenede Stater, 20889-5600
- Walter Reed National Military Medical Center
-
Easton, Maryland, Forenede Stater, 21601
- University of Maryland Shore Medical Center at Easton
-
-
Massachusetts
-
Burlington, Massachusetts, Forenede Stater, 01805
- Lahey Clinic
-
Lowell, Massachusetts, Forenede Stater, 01854
- Lowell General Hospital
-
Springfield, Massachusetts, Forenede Stater, 01199
- Baystate Medical Center
-
Winchester, Massachusetts, Forenede Stater, 01890
- Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care
-
Worcester, Massachusetts, Forenede Stater, 01605
- UMass Memorial Medical Center - Memorial Division
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Flint, Michigan, Forenede Stater, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Forenede Stater, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Forenede Stater, 48503
- Cancer Hematology Centers - Flint
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Forenede Stater, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Forenede Stater, 49007
- Bronson Methodist Hospital
-
Lansing, Michigan, Forenede Stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Traverse City, Michigan, Forenede Stater, 49684
- Munson Medical Center
-
-
Minnesota
-
Bemidji, Minnesota, Forenede Stater, 56601
- Sanford Joe Lueken Cancer Center
-
Duluth, Minnesota, Forenede Stater, 55805
- Essentia Health Cancer Center
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- University of Mississippi Medical Center
-
Jackson, Mississippi, Forenede Stater, 39202
- Mississippi Baptist Medical Center
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64111
- Saint Luke's Hospital of Kansas City
-
Springfield, Missouri, Forenede Stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forenede Stater, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Anaconda, Montana, Forenede Stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forenede Stater, 59101
- Billings Clinic Cancer Center
-
-
Nebraska
-
Grand Island, Nebraska, Forenede Stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Omaha, Nebraska, Forenede Stater, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Forenede Stater, 68198
- University of Nebraska Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Forenede Stater, 07920
- Memorial Sloan Kettering Basking Ridge
-
Camden, New Jersey, Forenede Stater, 08103
- Cooper Hospital University Medical Center
-
Lakewood, New Jersey, Forenede Stater, 08701
- Monmouth Medical Center Southern Campus
-
Livingston, New Jersey, Forenede Stater, 07039
- Cooperman Barnabas Medical Center
-
Long Branch, New Jersey, Forenede Stater, 07740
- Monmouth Medical Center
-
Middletown, New Jersey, Forenede Stater, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Forenede Stater, 07645
- Memorial Sloan Kettering Bergen
-
Neptune City, New Jersey, Forenede Stater, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rutgers Cancer Institute of New Jersey
-
Paramus, New Jersey, Forenede Stater, 07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood, New Jersey, Forenede Stater, 07450
- Neurosurgeons of New Jersey-Ridgewood
-
Ridgewood, New Jersey, Forenede Stater, 07450
- Valley Health System Ridgewood Campus
-
Somerville, New Jersey, Forenede Stater, 08876
- Robert Wood Johnson University Hospital Somerset
-
Toms River, New Jersey, Forenede Stater, 08755
- Community Medical Center
-
Voorhees Township, New Jersey, Forenede Stater, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
Wayne, New Jersey, Forenede Stater, 07470
- Valley Medical Group - Wayne Multispecialty Practice
-
Westwood, New Jersey, Forenede Stater, 07675
- Valley Health System-Hematology/Oncology
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Forenede Stater, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Bay Shore, New York, Forenede Stater, 11706
- Northwell Health Imbert Cancer Center
-
Brightwaters, New York, Forenede Stater, 11718
- Island Gynecologic Oncology
-
Brooklyn, New York, Forenede Stater, 11215
- New York-Presbyterian/Brooklyn Methodist Hospital
-
Buffalo, New York, Forenede Stater, 14263
- Roswell Park Cancer Institute
-
Commack, New York, Forenede Stater, 11725
- Memorial Sloan Kettering Commack
-
Flushing, New York, Forenede Stater, 11355
- The New York Hospital Medical Center of Queens
-
Harrison, New York, Forenede Stater, 10604
- Memorial Sloan Kettering Westchester
-
Lake Success, New York, Forenede Stater, 11042
- Northwell Health/Center for Advanced Medicine
-
Mineola, New York, Forenede Stater, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Forenede Stater, 11040
- Long Island Jewish Medical Center
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forenede Stater, 10029
- Mount Sinai Hospital
-
New York, New York, Forenede Stater, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Forenede Stater, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Forenede Stater, 10011
- Mount Sinai Chelsea
-
New York, New York, Forenede Stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Forenede Stater, 14642
- University of Rochester
-
Rochester, New York, Forenede Stater, 14620
- Highland Hospital
-
Staten Island, New York, Forenede Stater, 10305
- Staten Island University Hospital
-
Stony Brook, New York, Forenede Stater, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Forenede Stater, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Forenede Stater, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center - Moses Campus
-
Uniondale, New York, Forenede Stater, 11553
- Memorial Sloan Kettering Nassau
-
Valhalla, New York, Forenede Stater, 10595
- Westchester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Forenede Stater, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Clinton, North Carolina, Forenede Stater, 28328
- Southeastern Medical Oncology Center-Clinton
-
Concord, North Carolina, Forenede Stater, 28025
- Atrium Health Cabarrus/LCI-Concord
-
Goldsboro, North Carolina, Forenede Stater, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, Forenede Stater, 28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville, North Carolina, Forenede Stater, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Wilmington, North Carolina, Forenede Stater, 28401
- Novant Health New Hanover Regional Medical Center
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Forenede Stater, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44304
- Summa Health System - Akron Campus
-
Beachwood, Ohio, Forenede Stater, 44122
- UHHS-Chagrin Highlands Medical Center
-
Canton, Ohio, Forenede Stater, 44710
- Aultman Health Foundation
-
Centerville, Ohio, Forenede Stater, 45459
- Miami Valley Hospital South
-
Chardon, Ohio, Forenede Stater, 44024
- Geauga Hospital
-
Cincinnati, Ohio, Forenede Stater, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cincinnati, Ohio, Forenede Stater, 45220
- Good Samaritan Hospital - Cincinnati
-
Cleveland, Ohio, Forenede Stater, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Forenede Stater, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Forenede Stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Forenede Stater, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Forenede Stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Forenede Stater, 43219
- The Mark H Zangmeister Center
-
Mayfield Heights, Ohio, Forenede Stater, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, Forenede Stater, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Sylvania, Ohio, Forenede Stater, 43560
- ProMedica Flower Hospital
-
West Chester, Ohio, Forenede Stater, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westlake, Ohio, Forenede Stater, 44145
- UH Seidman Cancer Center at Saint John Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forenede Stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Bend, Oregon, Forenede Stater, 97701
- Saint Charles Health System
-
Ontario, Oregon, Forenede Stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Forenede Stater, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Forenede Stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forenede Stater, 97225
- Providence Saint Vincent Medical Center
-
Tualatin, Oregon, Forenede Stater, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Forenede Stater, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville, Pennsylvania, Forenede Stater, 17822
- Geisinger Medical Center
-
Ephrata, Pennsylvania, Forenede Stater, 17522
- Ephrata Cancer Center
-
Gettysburg, Pennsylvania, Forenede Stater, 17325
- Adams Cancer Center
-
Hanover, Pennsylvania, Forenede Stater, 17331
- WellSpan Medical Oncology and Hematology
-
Hazleton, Pennsylvania, Forenede Stater, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Jefferson Hills, Pennsylvania, Forenede Stater, 15025
- Jefferson Hospital
-
Johnstown, Pennsylvania, Forenede Stater, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
Lancaster, Pennsylvania, Forenede Stater, 17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster, Pennsylvania, Forenede Stater, 17602
- Lancaster General Hospital
-
Lebanon, Pennsylvania, Forenede Stater, 17042
- Sechler Family Cancer Center
-
Monroeville, Pennsylvania, Forenede Stater, 15146
- Forbes Hospital
-
Monroeville, Pennsylvania, Forenede Stater, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- UPMC-Magee Womens Hospital
-
Pottsville, Pennsylvania, Forenede Stater, 17901
- Geisinger Cancer Services-Pottsville
-
Scranton, Pennsylvania, Forenede Stater, 18510
- Community Medical Center
-
West Reading, Pennsylvania, Forenede Stater, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Forenede Stater, 15090
- Wexford Health and Wellness Pavilion
-
Wilkes-Barre, Pennsylvania, Forenede Stater, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
Willow Grove, Pennsylvania, Forenede Stater, 19090
- Asplundh Cancer Pavilion
-
York, Pennsylvania, Forenede Stater, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Forenede Stater, 17403
- WellSpan Health-York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Medical University of South Carolina
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forenede Stater, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Forenede Stater, 29601
- Saint Francis Hospital
-
Seneca, South Carolina, Forenede Stater, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, Forenede Stater, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Forenede Stater, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Forenede Stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, Forenede Stater, 77030
- Houston Methodist Hospital
-
Houston, Texas, Forenede Stater, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Houston, Texas, Forenede Stater, 77070
- Methodist Willowbrook Hospital
-
Houston, Texas, Forenede Stater, 77030
- Ben Taub General Hospital
-
Sugar Land, Texas, Forenede Stater, 77479
- Houston Methodist Sugar Land Hospital
-
The Woodlands, Texas, Forenede Stater, 77385
- Houston Methodist The Woodlands Hospital
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Forenede Stater, 84106
- University of Utah Sugarhouse Health Center
-
-
Vermont
-
Burlington, Vermont, Forenede Stater, 05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Forenede Stater, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Gig Harbor, Washington, Forenede Stater, 98335
- MultiCare Gig Harbor Medical Park
-
Kennewick, Washington, Forenede Stater, 99336
- Kadlec Clinic Hematology and Oncology
-
Puyallup, Washington, Forenede Stater, 98372
- MultiCare Good Samaritan Hospital
-
Renton, Washington, Forenede Stater, 98055
- Valley Medical Center
-
Seattle, Washington, Forenede Stater, 98122
- Swedish Medical Center-First Hill
-
Tacoma, Washington, Forenede Stater, 98405
- MultiCare Tacoma General Hospital
-
Vancouver, Washington, Forenede Stater, 98686
- Legacy Salmon Creek Hospital
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, Forenede Stater, 26506
- West Virginia University Healthcare
-
Morgantown, West Virginia, Forenede Stater, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Burlington, Wisconsin, Forenede Stater, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Germantown, Wisconsin, Forenede Stater, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Forenede Stater, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Forenede Stater, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, Forenede Stater, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Forenede Stater, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Forenede Stater, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Forenede Stater, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Forenede Stater, 54548
- Marshfield Medical Center - Minocqua
-
Oconomowoc, Wisconsin, Forenede Stater, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, Forenede Stater, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Forenede Stater, 53406
- Aurora Cancer Care-Racine
-
Rice Lake, Wisconsin, Forenede Stater, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Forenede Stater, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point, Wisconsin, Forenede Stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, Forenede Stater, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Forenede Stater, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha, Wisconsin, Forenede Stater, 53188
- UW Cancer Center at ProHealth Care
-
Wauwatosa, Wisconsin, Forenede Stater, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Forenede Stater, 53227
- Aurora West Allis Medical Center
-
Weston, Wisconsin, Forenede Stater, 54476
- Marshfield Medical Center - Weston
-
-
-
-
-
Saitama, Japan, 350-1298
- Saitama Medical University International Medical Center
-
-
Ehime
-
Tōon, Ehime, Japan, 791-0295
- Ehime University Hospital
-
-
Hiroshima
-
Kure, Hiroshima, Japan, 737
- Kure Medical Center and Chugoku Cancer Center
-
-
Niigata
-
Niigata, Niigata, Japan, 951-8520
- Niigata University Medical and Dental Hospital
-
-
-
-
-
San Juan, Puerto Rico, 00927
- Centro Comprensivo de Cancer de UPR
-
-
-
-
-
Daegu, Sydkorea, 41404
- Kyungpook National University Chilgok Hospital
-
Seoul, Sydkorea, 05505
- Asan Medical Center
-
Seoul, Sydkorea, 06273
- Gangnam Severance Hospital
-
Seoul, Sydkorea, 120-752
- Yonsei University Health System-Severance Hospital
-
Seoul, Sydkorea, 139-706
- Korea Cancer Center Hospital
-
-
Daegu
-
Dalseo-gu, Daegu, Sydkorea, 42601
- Keimyung University-Dongsan Medical Center
-
-
Gyeongsangnam-do
-
Seoul, Gyeongsangnam-do, Sydkorea, 51353
- Samsung Changwon Hospital
-
-
Kyeonggi-do
-
Seongnam, Kyeonggi-do, Sydkorea, 463-707
- Seoul National University Bundang Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.
-
Pathology report showing results of institutional MMR IHC testing.
-
Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.).
-
Submission of tumor specimens for centralized MMR IHC testing is required after Step 1 and before Step 2 registration.
-
In patients with measurable disease, lesions will be defined and monitored by RECIST version (v) 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.
-
Patients may have received
- NO prior chemotherapy for treatment of endometrial cancer OR
- Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) provided adjuvant chemotherapy was completed >= 12 months prior to STEP 2 registration.
-
Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to STEP 2 registration.
-
Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to STEP 2 registration.
-
Interval or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted.
-
Age >= 18.
-
Performance status of 0, 1 or 2.
-
Platelets >= 100,000/mcl.
-
Absolute neutrophil count (ANC) >= 1,500/mcl.
-
Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN).
-
Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled).
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN.
-
Thyroid stimulating hormone (TSH) within normal limits. If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal Free T4 level is required.
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of Step 2 registration are eligible for this trial.
-
For patients of child bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
-
Administration of study drugs (pembrolizumab [MK-3475], paclitaxel, carboplatin) may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from at least 14 days prior to Step 2 registration (for oral contraceptives), during treatment, and for 120 days after the last dose of study medication. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:
- Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
- Have a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to Step 2 registration; OR
- Have a congenital or acquired condition that prevents childbearing.
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information.
Exclusion Criteria:
-
Patients with prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents.
-
Patients who have a history of a severe hypersensitivity reaction to monoclonal antibody or pembrolizumab (MK-3475) and/or its excipients; and/or a severe hypersensitivity reaction to paclitaxel and/or carboplatin.
-
Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to Step 2 registration.
-
Patients who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Step 2 registration.
- Patients who have received steroids as CT scan contrast premedication may be enrolled.
- The use of inhaled or topical corticosteroids is allowed.
- The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
- The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to Step 2 registration and remain clinically stable.
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. This includes, but is not limited to, patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease.
-
Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible.
-
Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.
-
Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
-
Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; and cirrhosis.
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
Pregnant or lactating patients.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm I (placebo, paclitaxel, carboplatin)
COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions. |
Given IV
Andre navne:
Given IV
Andre navne:
Ancillary studies
Andre navne:
Given IV Ancillary studies Undergo CT scan
Andre navne:
|
|
Eksperimentel: Arm II (pembrolizumab, paclitaxel, carboplatin)
COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. |
Given IV
Andre navne:
Given IV
Andre navne:
Ancillary studies
Andre navne:
Ancillary studies Given IV
Andre navne:
Undergo CT scan
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival (PFS)
Tidsramme: Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.
|
Progression free survival (PFS) Note: For arm 2 (dMMR Cohort), the point estimate and the upper limit of the confidence interval are not able to be estimated due to insufficient events. |
Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Adverse Events With Grade 3 (or Higher)
Tidsramme: For the adverse event time frame, the interquartile range was (0.79 months, 3.42 months); the maximum was 28.39 months.
|
Assessed by Common Terminology Criteria for Adverse Events (CTCAE V5.0). The endpoint is the count of participants with an adverse event of grade 3 (or higher) by treatment group. |
For the adverse event time frame, the interquartile range was (0.79 months, 3.42 months); the maximum was 28.39 months.
|
|
Objective Tumor Response
Tidsramme: For the time frame for tumor response, the interquartile range was (2.27 months, 8.66 months) and the maximum was 36.37 months.
|
Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1. |
For the time frame for tumor response, the interquartile range was (2.27 months, 8.66 months) and the maximum was 36.37 months.
|
|
Duration of Objective Response
Tidsramme: For the duration of objective response, the interquartile range is (4.24 months, 7.92 months); the maximum is 28.68 months.
|
The time difference between the dates of first response and first progression; patients who do not progress are considered censored. Note: for Arm 2 (dMMR Cohort), the upper limit of the confidence interval is not able to be estimated due to an insufficient number of events. |
For the duration of objective response, the interquartile range is (4.24 months, 7.92 months); the maximum is 28.68 months.
|
|
Overall Survival (OS)
Tidsramme: Time from study entry to time of death or the date of last contact, assessed up to 5 years
|
Overall Survival (OS). This endpoint will be assessed by Kaplan-Meier. |
Time from study entry to time of death or the date of last contact, assessed up to 5 years
|
|
Quality of Life (QoL) in pMMR Patients Only
Tidsramme: 0-54 weeks from start of treatment
|
QoL are collected in pMMR patients only and measured with the Function Assessment of Cancer Therapy -Endometrial Trial Outcome Index (FACT En-TOI). The FACT-En TOI scores range 0 - 120 with a larger score suggesting better or favorable state of QOL. |
0-54 weeks from start of treatment
|
|
Concordance Between Institutional Mismatch Repair (MMR) Immunohistochemistry (IHC) Testing and Centralized MMR IHC
Tidsramme: IHC testing values (for both central and institutional) were collected at baseline.
|
Concordance between institutional MMR IHC testing and centralized MMR IHC. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics including the kappa statistic (e.g. Cohen's kappa coefficient). |
IHC testing values (for both central and institutional) were collected at baseline.
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Pembrolizumab Treatment and Self-reported Neurotoxicity
Tidsramme: 0-54 weeks from start of treatment
|
Patient-reported neurotoxicity will be measured with FACT/GOG-Ntx subscale (short form). |
0-54 weeks from start of treatment
|
|
Effect of Pembrolizumab on PFS and OS by Program Death Ligand 1 (PD-L1) IHC
Tidsramme: 5 years
|
Will assess the effect of pembrolizumab on PFS and OS by PD-L1 (combined positive score [CPS]) within proficient MMR (pMMR) and deficient MMR (dMMR) populations. The effectiveness of pembrolizumab will be compared by PD-L1 status (CPS). A formal test will be conducted by examining the interaction term between pembrolizumab treatment (yes or no) with PD-L1 status. The association between PD-L1 CPS status and MMR IHC status will be assessed with odds ratios. A test may be conducted with a Fisher's Exact Test, and confidence intervals will be provided. |
5 years
|
|
Association Between PD-L1 IHC and MMR Status
Tidsramme: 5 years
|
Measures of association between PD-L1 IHC (CPS) and MMR IHC status. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics such as kappa statistics (e.g. Cohen's kappa coefficient). |
5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Ramez N Eskander, NRG Oncology
Publikationer og nyttige links
Generelle publikationer
- Morton M, Marcu I, Levine M, Cosgrove C, Backes F, O'Malley D, Chambers L. Evaluation of Efficacy and Adverse Events After Second Immunotherapy Exposure in Endometrial and Cervical Carcinoma. Obstet Gynecol. 2023 Aug 1;142(2):360-363. doi: 10.1097/AOG.0000000000005243. Epub 2023 Jul 5.
- Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025 May;31(5):1539-1546. doi: 10.1038/s41591-025-03566-1. Epub 2025 Mar 5.
- Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27.
- Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024 May;35(5):414-428. doi: 10.1016/j.annonc.2024.02.006. Epub 2024 Feb 29.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Neoplasmer efter histologisk type
- Livmodersygdomme
- Kønssygdomme, kvindelige
- Genitale neoplasmer, kvindelige
- Uterine neoplasmer
- Sarkom
- Neoplasmer, bindevæv og blødt væv
- Neoplasmer, komplekse og blandede
- Endometriale neoplasmer
- Carcinosarkom
- Organiske kemikalier
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Koordinationskomplekser
- Taxoider
- Cyclodecanes
- Diterpenes
- Sundhedsøkonomi og organisationer
- Økonomi
- Carboplatin
- Paclitaxel
- pembrolizumab
- Skatter
Andre undersøgelses-id-numre
- NCI-2019-02186
- U10CA180868 (U.S. NIH-bevilling/kontrakt)
- NCI-2019-02186 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- NRG-GY018 (Anden identifikator: CTEP)
- NRG-GY018 (Anden identifikator: NRG Oncology)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .